Cancer-associated fibroblasts (CAFs) reside in cancer tissues and have been demonstrated to influence cancer growth and invasion of various organs, including lung cancer, as well as to promote resistance to drug therapies such as EGFR-TKIs; therefore, CAFs have attracted attention as new therapeutic targets. This evidence concerns the gene EGFR and lung carcinoma.